Interaction between serotonin 5-HT1A receptors and β-endorphins modulates antidepressant response

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 8, 2008, Pages 1804-1809

  Navinés, Ricard ^a,b   Martín Santos, Rocío ^a,b   Gómez Gil, Esther ^a   Martínez de Osaba, María J ^a   Gastó, Cristòbal ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

END; 5HT1A receptors; Antidepressant response; Buspirone challenge; Citalopram; Major depression

Indexed keywords

BETA ENDORPHIN; BUSPIRONE; CITALOPRAM; SEROTONIN 1A RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; TREATMENT DURATION;

ADOLESCENT; ADULT; BETA-ENDORPHIN; BUSPIRONE; CASE-CONTROL STUDIES; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; MALE; MIDDLE AGED; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS; YOUNG ADULT;

EID: 56449098743     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.07.021     Document Type: Article

References (40)

1. Alexopoulus G.S., Inturrisi C.E., Lipman R., Frances R., Haycox J., Dougherty J.H., et al. Plasma immunoreactive beta-endorphin levels in depression. Effect of electroconvulsive therapy. Arch Gen Psychiatry 40 (1983) 181-183
2. Anderson I.M., Cowen P.J., and Grahame-Smith D.G. The effects of gepirone on neuroendocrine function and temperature in humans. Psychopharmacology 100 (1990) 498-503
3. Anderson I.M., Deakin J.F.W., and Miller H.J. The effect of chronic fluvoxamine on hormonal and psychological responses to buspirone en normal volunteers. Psychopharmacology 28 (1996) 74-82
4. Arborelius L., Owens M.J., Plotsky P.M., and Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160 (1999) 1-12
5. Bagdy G., Calogero A.E., Szemeredi K., Gomez M.T., Murphy D.L., Chrousos G.P., et al. Beta-endorphin responses to different serotonin agonists: involvement of corticotropin-releasing hormone, vasopressin and direct pituitary action. Brain Res 537 (1990) 227-232
6. Blier P., and de Montigny. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15 (1994) 220-226
7. Bodnar R.J., and Klein G.E. Endogenous opiates and behavior. Peptides 27 (2005) 3391-3478
8. Carney M.W.P., Roth M., and Garside R.F. The diagnosis of depressive syndromes and the prediction of ECT response. Br J Psychiatry 111 (1965) 659-674
9. 1A receptor sensitivity in major depression. A neuroendocrine study with buspirone. Br J Psychiatry 164 (1994) 372-379
10. Darko D.F., Irwin M.R., Risch S.C., and Gillin J.C. Plasma beta endorphin and natural killer cell activity in major depression: a preliminary study. Psychiatry Res 43 (1992) 111-119
11. First M., Spitzer R., Gibbon M., and Williams J. Structured clinical interview for DSM-IV Axis I Disorders-Patients Edition (SCID-I/P, Version 2.0) (1995), New York State Psychiatric Institute, New York
12. Goodwin G.M., Austin M.P., Curran S.M., Ross M., Murray C., Prentice N., et al. The elevation of plasma beta-endorphin levels in major depression. J Affect Disord 29 (1993) 281-289
13. Djurovic D., Milic-Askrabic J., and Majkic-Singh N. Serum beta-endorphin level in patients with depression on fluvoxamine. Farmaco 31 (1999) 130-133
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23 (1960) 56-62
15. Heuser I.J., Schweiger U., Gotthardt U., Schmider J., Lammers C.H., Dettling M., et al. Pituitary-adrenal system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry 153 (1996) 93-99
16. Holsboer F., and Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17 (1996) 187-205
17. Jørgensen H., Knigge U., Kjaer A., Møller M., and Warberg J. Serotonergic stimulation of corticotropin-releasing hormone and pro-opiomelanocortin gene expression. J Neuroendocrinol 14 (2002) 788-795
18. Kennedy S.E., Koeppe R.A., Young E.A., and Zubieta J.K. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 63 (2006) 1199-1208
19. Kitamura Y., Kitagawa K., Fujitani Y., Shibata K., Araki H., Sendou T., et al. The 5-HT1A receptor full agonist, 8-OH-DPAT inhibits ACTH-induced 5-HT2A receptor hyperfunction in rats: involvement of 5-HT1A receptors in the DOI-induced wet-dog shakes in ACTH-treated rats. Biol Pharm Bull 30 (2007) 117-120
20. Koening J.I., Gudelsky G.A., and Meltzer H.Y. Stimulation of corticosterone and beta-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur J Pharmacology 137 (1987) 1-8
21. 1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge. Neuropsychopharmacology 20 (1999) 629-639
22. 1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 28 (1990) 620-628
23. Maes M., Van Gastel A., Ranjan R., Blockx P., Cosyns P., Meltzer H.Y., et al. Stimulatory effects of L-5-hydroxytryptophan on postdexamethasone beta-endorphin levels in major depression. Neuropsychopharmacology 15 (1996) 340-348
24. Maes M., Van Gastel A., Meltzer H.Y., Cosyns P., Blockx P., and Desnyder R. Acute administration of buspirone increases the escape of hypothalamic-pituitary-adrenal-axis hormones from suppression by dexamethasone in depression. Psychoneuroendocrinology 21 (1996) 67-81
25. Majeed N.H., Lason W., Przewlocka B., and Przewlocki R. Differential modulation of the beta-endorphin and dynorphin systems by serotonergic simulation in the rat. Neuropeptides 5 (1985) 563-566
26. Meltzer H.Y., and Maes M. Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Biol Psychiatry 35 (1994) 316-323
27. Meltzer H.Y., and Maes M. Effects of ipsapirone on plasma cortisol and body temperature in major depression. Biol Psychiatry 38 (1995) 450-457
28. Micó J.A., Ardid D., Berrocoso E., and Eschalier A. Antidepresssants and pain. Trends Pharmacol Sci 27 (2005) 348-354
29. Moeller F., Steinberg J.L., Fulton M., Kramer G., and Petty F. A preliminary neuroendocrine study with buspirone in major depression. Neuropsychopharmacology 10 (1994) 75-83
30. Navinés R., Gómez-Gil E., Martín-Santos R., Martínez de Osaba M.J., Escolar G., and Gastó C. Hormonal response to buspirone is not impaired in major depression. Hum Psychopharmacol 22 (2007) 389-395
31. 1A receptor agonist buspirone in patients with major depression and therapeutic response. Psychoneuroendocrinology 32 (2007) 411-416
32. Pintor L., Torres X., Navarro V., Martinez de Osaba M.A., Matrai S., and Gastó C. Corticotropin-releasing factor test in melancholic patients in depressed state versus recovery: a comparative study. Prog Neuro-Psychopharmacol Biol Psychiatry 31 (2007) 1027-1033
33. Riedel W.J., Klaassen T., Griez E., Honing A., Menheere P.P.C.A., and van Praag H.M. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood. Neuropsychopharmacology 26 (2002) 358-367
34. 1A receptor sensitivity. Psychopharmacology 132 (1997) 296-302
35. Shapira B., Newman M.E., Gelfin Y., and Lerer B. Blunted temperature and cortisol responses to ipsapirone in major depression: lack of enhancement by electroconvulsive therapy. Psychoneuroendocrinology 25 (2000) 421-438
36. Shin Shiah I., Yatham L.N., Lam R.W., and Zis A.P. Cortisol, hypothermic and behavioral responses to ipsapirone in patients with bipolar depression and normal controls. Neuropsychobiology 38 (1998) 6-12
37. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., and Akil H. Hormonal evidence for altered responsiveness to social stress in major depression. Neuropsychopharmacology 23 (2000) 411-418
38. Young E.A., Altemus A., Lopez J.K., Kocsis J.H., Schatzberg A.F., DeBattista C., and Zubieta J.K. HPA axis activation in major depression and response to fluoxetine. Psychoneuroendocrinology 29 (2004) 1198-1204
39. Zangen A., Nakash R., Roth-Deri I., Overstreet D.H., and Yadid G. Impaired release of β-endorphin in response to serotonin in a rat model of depression. Neurosciences 110 (2002) 389-393
40. Zubieta J.K., Smith Y.R., Bueller J.A., Xu Y., Kilbourn M.R., Jewett D.M., et al. Regional mu-opioid receptor regulation of sensory and affective dimensions of pain. Science 293 (2001) 311-315